The Medicines and Healthcare Products Regulatory Agency (MHRA) has issued an alert regarding a particular batch of the medication Bydureon (Exenatide), following a review which indicates that this batch may contain a very small number of under-filled vials.
The affected batch is:
The low fills, manufactured by Bristol-Myers Squibb and Astra Zeneca, impact approximately 0.2 per cent of the batch and range between 30 and 75 per cent of the labeled dose. If you come across stocks of the affected batch, they should be returned to the original supplier.
- For enquiries relating to stock returns, please contact your original suppliers local service center.
- For medical information enquiries, please call Bristol-Myers Squibb and Astra Zeneca on 0800 731 1736 or by email email@example.com